A Phase 1 Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies - Regional Cancer Care Associates LLC

Clinical Trials

A Phase 1 Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies

Type of Cancer
Multiple Myeloma
Locations
Hackensack
Sponsor
Sanofi Aventis
Protocol Number
TED10893
Cancer Diagnosis
To Learn More Call
201-510-0910